Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Vertex Pharmaceuticals Inc Market Cap
Based on ratings from 27 stock analysts, the Vertex Pharmaceuticals Inc stock price is expected to increase by 14.18% in 12 months. This is calculated by using the average 12-month stock price forecast for Vertex Pharmaceuticals Inc. The lowest target is $325 and the highest is $600. Please note analyst price targets are not guaranteed and could be missed completely.
Vertex Pharmaceuticals Inc has a total of 27 Wall St Analyst ratings. There are 22 buy ratings, 5 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Vertex Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of VRTX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Brian Abrahams RBC Capital | Sector Perform | $425 | Maintains | Oct 4, 2024 |
| Matthew Harrison Morgan Stanley | Equal-Weight | $474 | Maintains | Oct 1, 2024 |
| Brian Abrahams RBC Capital | Sector Perform | $431 | Reiterates | Sep 19, 2024 |
| Jessica Fye JP Morgan | Overweight | $510 | Maintains | Aug 5, 2024 |
| Gena Wang Barclays | Equal-Weight | $509 | Downgrade | Aug 5, 2024 |
| Joon Lee Truist Securities | Buy | $550 | Reiterates | Aug 5, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $600 | Maintains | Aug 5, 2024 |
| Hartaj Singh Oppenheimer | Outperform | $550 | Maintains | Aug 5, 2024 |
| Olivia Brayer Cantor Fitzgerald | Overweight | $480 | Reiterates | Aug 2, 2024 |
| Debjit Chattopadhyay Guggenheim | Buy | $558 | Maintains | Aug 2, 2024 |
| Christopher Raymond Piper Sandler | Overweight | $535 | Maintains | Aug 2, 2024 |
| Whitney Ijem Canaccord Genuity | Sell | $376 | Maintains | Jul 31, 2024 |
| Joseph Stringer Needham | Hold | Reiterates | Jul 26, 2024 | |
| Phil Nadeau TD Cowen | Buy | $500 | Maintains | Jul 23, 2024 |
| Olivia Brayer Cantor Fitzgerald | Overweight | $480 | Maintains | Jul 22, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $500 | Maintains | Jul 19, 2024 |
| Matthew Harrison Morgan Stanley | Equal-Weight | $455 | Maintains | Jul 11, 2024 |
| Steve Chesney Redburn Atlantic | Buy | $545 | Initiates | Jun 27, 2024 |
| Mohit Bansal Wells Fargo | Overweight | $555 | Maintains | Jun 24, 2024 |
| Jasper Hellweg Argus Research | Buy | $550 | Maintains | Jun 17, 2024 |
When did it IPO
1991
Staff Count
5,400
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Reshma Kewalramani FASN, M.D.
Market Cap
$117.52B
In 2023, VRTX generated $9.87B in revenue, which was a increase of 10.51% from the previous year. This can be seen as a signal that VRTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 30 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Vertex Pharmaceuticals (VRTX) closed at $465.08, up 0.48% from the previous trading day.
Why It Matters - A 0.48% increase in Vertex Pharmaceuticals' stock price indicates positive market sentiment, which could attract more investors and influence future trading activity.
Thu, 26 Sep 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Wall Street analysts' recommendations significantly influence stock prices, guiding investors on buy, sell, or hold decisions, especially when ratings change.
Why It Matters - Analyst ratings influence stock prices, impacting investment decisions. Changes in these recommendations can lead to market volatility, affecting portfolio value.
Thu, 26 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vertex Pharmaceuticals will present Phase 3 data on its investigational drug, vanzacaftor/tezacaftor/deutivacaftor, at the North American Cystic Fibrosis Conference, alongside long-term CF outcomes data.
Why It Matters - The acceptance of Phase 3 data presentations for Vertex's new CF treatment could signal advancements in their pipeline, potentially impacting stock performance and market positioning.
Mon, 23 Sep 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Vertex Pharmaceuticals (VRTX) closed at $460, reflecting a decline of 1.06% from the prior trading session.
Why It Matters - A 1.06% drop in Vertex Pharmaceuticals' stock may indicate market volatility or investor concerns, potentially impacting future performance and investment decisions.
Wed, 25 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Vertex (VRTX) has gained significant attention from Zacks.com users, indicating potential investor interest that may impact the stock's future performance.
Why It Matters - Increased interest in Vertex (VRTX) on Zacks.com signals potential investor sentiment, which may influence stock performance and trading volume.
Mon, 23 Sep 2024
Sentiment - POSITIVE
Source - 24/7 Wall Street
Summary - Pharma stocks have gained momentum over the past year due to new drug innovations and improved operational efficiency, attracting investor interest for growth opportunities.
Why It Matters - Pharma stocks are experiencing growth due to new drug innovations and improved operational efficiency, signaling potential investment opportunities in a revitalized sector.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
